December 12: The Week in Cancer News
The addition of targeted therapy helps control metastatic breast cancer, and a pair of immunotherapy drugs prolongs survival in multiple myeloma.
Progress Against Cancer
The addition of targeted therapy helps control metastatic breast cancer, and a pair of immunotherapy drugs prolongs survival in multiple myeloma.
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with BRCA1/2 mutations.
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
New insights into the neurologic and physiologic impact of chronic stress on ovarian cancer were presented at two recent AACR conferences.
In November, the AACR’s journal editors highlighted studies on sucralose limiting immunotherapy, benefits of caloric restriction, and more.
Shawn Lee, MD, PhD, an AACR-St. Baldrick’s Foundation Grantee, is working to personalize therapies for children with acute lymphoblastic leukemia.
More people with breast cancer can forgo radiation after surgery, and a treatment combination helps control esophageal cancer.
Promising early-phase clinical trial data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Researchers are exploring innovative early cancer detection strategies involving tiny cancer hunters, the voice, electronic noses, and more.
Adding chemotherapy to targeted therapy improves outcomes for people with advanced EGFR-positive non-small cell lung cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More